Alecensa Den Europæiske Union - dansk - EMA (European Medicines Agency)

alecensa

roche registration gmbh - alectinibhydrochlorid - carcinom, ikke-småcellet lunge - antineoplastiske midler - alecensa som monoterapi er indiceret til førstegangsbehandling af voksne patienter med anaplastisk lymfomkinase (alk) -positive avanceret ikke-småcellet lungecancer (nsclc). alecensa som monoterapi er indiceret til behandling af voksne patienter med alk‑positive avanceret nsclc, der tidligere er behandlet med crizotinib.

Inlyta Den Europæiske Union - dansk - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - axitinib - carcinom, nyrecelle - protein kinase hæmmere - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Flecin 50 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

flecin 50 mg tabletter

orifarm a/s - flecainidacetat - tabletter - 50 mg

Tambocor 10 mg/ml injektionsvæske Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tambocor 10 mg/ml injektionsvæske

meda as - flecainidacetat - injektionsvæske - 10 mg/ml

Tambocor 100 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tambocor 100 mg tabletter

mylan denmark aps - flecainidacetat - tabletter - 100 mg

Tambocor 50 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tambocor 50 mg tabletter

mylan denmark aps - flecainidacetat - tabletter - 50 mg

Tempinix 100 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tempinix 100 mg tabletter

2care4 aps - flecainidacetat - tabletter - 100 mg

Flenoprim 100 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

flenoprim 100 mg tabletter

nordic prime aps - flecainidacetat - tabletter - 100 mg

Lorviqua Den Europæiske Union - dansk - EMA (European Medicines Agency)

lorviqua

pfizer europe ma eeig - lorlatinib - carcinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Bavencio Den Europæiske Union - dansk - EMA (European Medicines Agency)

bavencio

merck europe b.v. - avelumab - neuroendocrine tumorer - andre antineoplastiske midler, monoklonale antistoffer - bavencio er indiceret som monoterapi til behandling af voksne patienter med metastatisk merkel cellecarcinom (mcc). bavencio i kombination med axitinib er angivet for den første linje behandling af voksne patienter med fremskredent renalcellecarcinom (rcc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.